There are 2949 resources available
345P - Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
Presenter: Ursula Hasler-Strub
Session: E-Poster Display
Resources:
Abstract
346P - Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion
Presenter: Kenji Tamura
Session: E-Poster Display
Resources:
Abstract
347P - Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
Presenter: Martine Piccart
Session: E-Poster Display
Resources:
Abstract
348P - First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Daniel Eiger
Session: E-Poster Display
Resources:
Abstract
349TiP - EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
Presenter: Priyanka Sharma
Session: E-Poster Display
Resources:
Abstract
350TiP - A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)
Presenter: Nicholas Turner
Session: E-Poster Display
Resources:
Abstract
351TiP - SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
Presenter: Mafalda Oliveira
Session: E-Poster Display
Resources:
Abstract
352TiP - EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract
353TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract
354TiP - Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
Presenter: Federico Rojo Todo
Session: E-Poster Display
Resources:
Abstract